The earnings results for ImmunoPrecise Antibodies IPA for Q2 were made public on Tuesday, December 10, 2024 at 08:30 AM.
Here’s a comprehensive overview of the announcement.
Earnings
ImmunoPrecise Antibodies missed estimated earnings by -40.0%, reporting an EPS of $-0.07 versus an estimate of $-0.05.
Revenue was down $136 thousand from the same period last year.
Analysis of Past Earnings
Last quarter the company missed on EPS by $0.03 which was followed by a 7.000000000000001% increase in the share price the next day.
Here’s a look at ImmunoPrecise Antibodies’s past performance:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.08 | -0.08 | -0.07 | -0.100 |
| EPS Actual | -0.11 | -0.58 | -0.08 | -0.074 |
| Revenue Estimate | 4.96M | 4.72M | 4.50M | 4.33M |
| Revenue Actual | 3.87M | 4.72M | 4.55M | 4.62M |
To track all earnings releases for ImmunoPrecise Antibodies visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
